$22.35
15.68% today
Nasdaq, Oct 02, 10:18 pm CET
ISIN
US8036071004
Symbol
SRPT

Sarepta Therapeutics, Inc. Stock price

$19.32
+1.12 6.15% 1M
-42.59 68.79% 6M
-102.27 84.11% YTD
-103.01 84.21% 1Y
-90.62 82.43% 3Y
-122.23 86.35% 5Y
-19.96 50.81% 10Y
+2.70 16.25% 20Y
Nasdaq, Closing price Wed, Oct 01 2025
+0.05 0.26%

Key metrics

Basic
Market capitalization
$1.9b
Enterprise Value
$2.2b
Net debt
$339.3m
Cash
$800.1m
Shares outstanding
97.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.8 | 0.9
EV/Sales
0.9 | 1.1
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
38.6%
Return on Equity
15.4%
ROCE
0.0%
ROIC
-0.1%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$2.5b | $2.1b
EBITDA
$1.5m | $-320.7m
EBIT
$-932.0k | $-440.2m
Net Income
$-58.0m | $-438.3m
Free Cash Flow
$-454.0m
Growth (TTM | estimate)
Revenue
64.9% | 10.8%
EBITDA
-96.2% | -245.4%
EBIT
-102.5% | -301.8%
Net Income
-222.5% | -286.3%
Free Cash Flow
14.0%
Margin (TTM | estimate)
Gross
79.3%
EBITDA
0.1% | -15.2%
EBIT
0.0%
Net
-2.3% | -20.8%
Free Cash Flow
-18.3%
More
EPS
$-0.5
FCF per Share
$-4.6
Short interest
22.5%
Employees
1k
Rev per Employee
$1.4m
Show more

Is Sarepta Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Sarepta Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

36 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

13x Buy
36%
18x Hold
50%
5x Sell
14%

Analyst Opinions

36 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

Buy
36%
Hold
50%
Sell
14%

Financial data from Sarepta Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,482 2,482
65% 65%
100%
- Direct Costs 514 514
192% 192%
21%
1,967 1,967
48% 48%
79%
- Selling and Administrative Expenses 564 564
9% 9%
23%
- Research and Development Expense 1,402 1,402
82% 82%
57%
1.54 1.54
96% 96%
0%
- Depreciation and Amortization 2.47 2.47
4% 4%
0%
EBIT (Operating Income) EBIT -0.93 -0.93
102% 102%
0%
Net Profit -58 -58
222% 222%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Sarepta Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sarepta Therapeutics, Inc. Stock News

Neutral
Business Wire
2 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2025 (the “Grant Date”) that were approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired...
Neutral
PRNewsWire
8 days ago
NEW YORK , Sept. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT)  breached their fiduciary duties to shareholders.
Negative
The Motley Fool
27 days ago
Just because a stock has been battered doesn't make it an automatic buy. That's only the case if it can bounce back, and in some cases, there are few good reasons to believe it can.
More Sarepta Therapeutics, Inc. News

Company Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Head office United States
CEO Douglas Ingram
Employees 1,372
Founded 1980
Website www.sarepta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today